Lilly heart drug Effient fails to carve new niche
MUNICH (Reuters) - Eli Lilly's new heart drug Effient failed to beat the older product Plavix in a head-to-head clinical study, dashing hopes for its expanded use in treating less critically sick heart patients. The finding, released at a medical meeting on Sunday, is good news for rival AstraZeneca, whose competitor product Brilinta did show an edge over Plavix in a comparable group of patients in an analysis published last year. ...
Source: news.yahoo.com
No comments:
Post a Comment